Sobi - Swedish Orphan Biovitrum AB (publ) · 17 hours ago
Data Science and Advanced Analytics Internship (hybrid)
Sobi is a global biopharmaceutical company dedicated to rare diseases, and they are seeking interns for their Data Science and Advanced Analytics program. The internship offers a unique perspective into the pharmaceutical industry, allowing interns to contribute to analytics and AI initiatives that support sales and marketing business needs.
BiotechnologyGeneticsMedicalPharmaceutical
Responsibilities
Use deep analytics and AI type initiatives to support sales and marketing business needs
Deadline-driven with a high level of organizational and planning skills
Strong analytical, problem-solving, and oral and written communication skills
Ability to work well in teams, effectively manage projects, and present ideas clearly and concisely
Global mindset to grow in a diverse work environment
Excellent communication and leadership skills
Other specific responsibilities will be dependent upon the needs of the mentor and qualifications/skillset of the candidate
Qualification
Required
Candidates must be currently enrolled at an accredited university in the Boston metro area
Must be authorized to work in the US without sponsorship (i.e., Sobi, Inc. will not sponsor interns)
Minimum GPA 3.0
Must be undergraduate students with at least 2 years of university studies before internship
Return to university for at least one semester post-internship
Preferred
Preferred Majors include Advanced Analytics or Mathematics
Benefits
Competitive compensation for your work
Generous time off policy
Opportunity to broaden your horizons by attending popular conferences
Emphasis on work/life balance
Collaborative and team-oriented environment
Making a positive impact to help ultra-rare disease patients who are in need of life saving treatments
Company
Sobi - Swedish Orphan Biovitrum AB (publ)
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Funding
Current Stage
Public CompanyTotal Funding
$825.99M2024-05-08Post Ipo Debt· $274.92M
2023-08-22Post Ipo Equity· $551.07M
2006-09-15IPO
Leadership Team
Guido Oelkers
Chief Executive Officer
Recent News
PR Newswire
2026-01-16
News Powered by Cision
2026-01-16
Company data provided by crunchbase